Epilive Syrup contains Levetiracetam 100 mg/ml, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby stabilizing neuronal activity and reducing seizure frequency. Epilive Syrup is formulated for oral administration, offering a convenient dosing option for pediatric and adult patients who require flexible dose adjustments. The syrup formulation facilitates accurate dosing in patients who have difficulty swallowing tablets. Epilive Syrup is generally well tolerated; common adverse effects may include somnolence, dizziness, fatigue, and behavioral changes such as irritability or agitation. It is essential to initiate therapy under medical supervision with gradual dose titration to minimize adverse effects. Dose adjustments may be necessary in patients with renal impairment. Epilive Syrup should be used as part of a comprehensive epilepsy management plan, including regular monitoring and adherence to prescribed therapy. Patients should be advised not to discontinue treatment abruptly to avoid increased seizure risk. Consult a healthcare professional before use to ensure suitability and to discuss potential drug interactions.